132 related articles for article (PubMed ID: 30124545)
1. Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment: a multicentre experience.
Maeremans J; Cottens D; Azzalini L; Pereira B; Godino C; Carlino M; Colombo A; Frambach P; Bellini B; Candilio L; Briguori C; Pierri A; Lamers S; Roux L; Duponselle J; Vrolix M; Dens J
J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):564-570. PubMed ID: 30124545
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
[TBL] [Abstract][Full Text] [Related]
3. Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.
van Houwelingen KG; Sen H; Lam MK; Tandjung K; Löwik MM; de Man FH; Louwerenburg JH; Stoel MG; Hartmann M; Linssen GC; Doggen CJ; von Birgelen C
Catheter Cardiovasc Interv; 2015 Feb; 85(3):E76-82. PubMed ID: 25339110
[TBL] [Abstract][Full Text] [Related]
4. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
[TBL] [Abstract][Full Text] [Related]
5. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry.
Sardella G; Stella P; Chiarito M; Leone AM; Balian V; Prosperi F; Sorropago G; Mancone M; Calcagno S; Briguori C; Stefanini GG
Catheter Cardiovasc Interv; 2018 Apr; 91(5):884-891. PubMed ID: 28707375
[TBL] [Abstract][Full Text] [Related]
7. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
[TBL] [Abstract][Full Text] [Related]
8. Zotarolimus compared with everolimus eluting stents-angiographic and clinical results after recanalization of true coronary chronic total occlusions.
Markovic S; Lützner M; Rottbauer W; Wöhrle J
Catheter Cardiovasc Interv; 2016 Jul; 88(1):18-23. PubMed ID: 26945903
[TBL] [Abstract][Full Text] [Related]
9. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
10. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
[TBL] [Abstract][Full Text] [Related]
11. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions).
Kandzari DE; Kini AS; Karmpaliotis D; Moses JW; Tummala PE; Grantham JA; Orr C; Lombardi W; Nicholson WJ; Lembo NJ; Popma JJ; Wang J; Larracas C; Rutledge DR
JACC Cardiovasc Interv; 2015 May; 8(6):761-769. PubMed ID: 25912400
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Polymer-Free Drug-Eluting Stents.
Chiarito M; Sardella G; Colombo A; Briguori C; Testa L; Bedogni F; Fabbiocchi F; Paggi A; Palloshi A; Tamburino C; Margonato A; Pivato CA; Baber U; Calcagno S; Giordano A; Godino C; Stefanini GG
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007311. PubMed ID: 30767663
[TBL] [Abstract][Full Text] [Related]
15. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
[TBL] [Abstract][Full Text] [Related]
16. Incidence, predicting factors, and clinical outcomes of periprocedural myocardial infarction after percutaneous coronary intervention for chronic total occlusion in the era of new-generation drug-eluting stents.
Kim JH; Kim BK; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Catheter Cardiovasc Interv; 2018 Sep; 92(3):477-485. PubMed ID: 29266736
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
18. Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.
Kelbæk H; Holmvang L; Richardt G; Eberli FR; Stella P; Buszman PE; Neumann FJ; Serruys PW; Windecker S; Widimský P; Belardi JA; Silber S
EuroIntervention; 2015 Oct; 11(6):650-7. PubMed ID: 25033102
[TBL] [Abstract][Full Text] [Related]
19. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).
Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A
Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802
[TBL] [Abstract][Full Text] [Related]
20. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients: Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTre rEgistry).
Colombo A; Godino C; Donahue M; Testa L; Chiarito M; Pavon AG; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Margonato A; Briguori C
Int J Cardiol; 2016 Jul; 214():113-20. PubMed ID: 27060269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
